151
Views
6
CrossRef citations to date
0
Altmetric
Original Research

12-month outcomes of the US patient cohort in the SONATA pivotal IDE trial of transcervical ablation of uterine fibroids

, , , &
Pages 387-394 | Published online: 05 Jul 2019

References

  • Chudnoff S, Guido R, Roy K, Levine D, Mihalov L, Garza-Leal JG. Ultrasound-guided transcervical ablation of uterine leiomyomas. Obstet Gynecol. 2019;133:13–22. doi:10.1097/AOG.000000000000303230531573
  • Brölmann H, Bongers M, Garza-Leal JG, et al. The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids. Gynecol Surg. 2016;13:27–35. doi:10.1007/s10397-015-0915-326918001
  • Bongers M, Brölmann H, Gupta J, Garza-Leal JG, Toub D. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate® system: three- and six-month endpoint results from the FAST-EU study. Gynecol Surg. 2015;12:61–70. doi:10.1007/s10397-014-0873-125774122
  • Garza-Leal JG, Toub D, León IH, et al. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate system: safety, tolerability, and ablation results in a closed abdomen setting. Gynecol Surg. 2011;8:327–334. doi:10.1007/s10397-010-0655-3
  • Toub DB. A new paradigm for uterine fibroid treatment: transcervical, intrauterine sonography-guided radiofrequency ablation of uterine fibroids with the sonata system. Curr Obstet Gynecol Rep. 2017;6:67–73. doi:10.1007/s13669-017-0194-228357157